{"disease":{"id":"small-lymphocytic-leukemia-sll","name":"small lymphocytic leukemia sll"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06967610","title":"Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04198415","title":"A Study of the Safety and Efficacy of Venetoclax in Japanese Participants With Relapsed and Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Leukemia)","phase":"","overall_status":"COMPLETED","enrollment_count":4,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT04209621","title":"Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":true}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}